↓ Skip to main content

Dove Medical Press

Article Metrics

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study

Overview of attention for article published in Neuropsychiatric Disease and Treatment, June 2015
Altmetric Badge

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
12 Dimensions

Readers on

mendeley
36 Mendeley
Title
Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
Published in
Neuropsychiatric Disease and Treatment, June 2015
DOI 10.2147/ndt.s81760
Pubmed ID
Authors

Yu Feng, Tianmei Si, Kerang Zhang, Jisheng Tang, Maosheng Fang, Keqing Li, Jianmin Zhuo

Abstract

This open-label, single-arm, multicenter, 13-week, prospective study explored the efficacy, safety, and tolerability of paliperidone palmitate (150 milligram equivalents [mg eq] [day 1], 100 mg eq [day 8], both deltoid injections; 75-150 mg eq, deltoid/gluteal injection) in Chinese patients with acute schizophrenia (Positive and Negative Syndrome Scale [PANSS] total score ≥70), who previously had unsatisfactory therapeutic effect following oral antipsychotic treatment (without washout period). Primary efficacy endpoint was percentage of patients with ≥30% improvement in the PANSS total score at the end of 13 weeks. Secondary efficacy endpoints included change from baseline to end of week 13 in PANSS total score, PANSS subscale scores, Marder factor scores, Clinical Global Impressions-Severity score, and Personal and Social Performance Scale scores. Overall, 477/610 enrolled patients (full analysis set, 78.2%) completed the study (men: 55.1%; women: 44.9%; mean age: 31.5 years). Total, 443/610 (72.6%, full analysis set) patients achieved primary endpoint (mean [standard deviation] change from baseline: -30.9 [19.51]). All secondary endpoints demonstrated significant improvement at the end of 13 weeks. One death occurred during this acute phase. The most common (>5%) treatment-emergent adverse events were extrapyramidal disorders (8.4%). The efficacy and safety data are consistent with other short-term, placebo-controlled studies of paliperidone palmitate conducted in similar populations.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Unknown 35 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 6 17%
Student > Bachelor 5 14%
Student > Doctoral Student 5 14%
Researcher 3 8%
Student > Ph. D. Student 3 8%
Other 5 14%
Unknown 9 25%
Readers by discipline Count As %
Medicine and Dentistry 8 22%
Psychology 7 19%
Pharmacology, Toxicology and Pharmaceutical Science 4 11%
Nursing and Health Professions 2 6%
Business, Management and Accounting 1 3%
Other 2 6%
Unknown 12 33%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 July 2015.
All research outputs
#11,518,858
of 14,535,828 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,790
of 2,442 outputs
Outputs of similar age
#159,308
of 233,207 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#93
of 98 outputs
Altmetric has tracked 14,535,828 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,442 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,207 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 98 others from the same source and published within six weeks on either side of this one. This one is in the 2nd percentile – i.e., 2% of its contemporaries scored the same or lower than it.